重性抑郁障碍持续抗抑郁药使用的遗传与表型关联
该回顾性队列研究纳入澳大利亚抑郁遗传学研究中的成年重性抑郁障碍参与者,分析44项自报表型与15项多基因评分与抗抑郁药治疗复杂性和持续使用360天的关联。高治疗复杂度与37项表型及精神科特质多基因评分相关,持续使用亚组表型各异,并发现免疫相关基因位点与SSRI持续使用相关。
要点
- 高治疗复杂度与吸烟、复发、自杀意念、慢性疼痛及非典型抑郁等37项表型相关。
- 精神科特质多基因评分与治疗复杂度相关,但与持续使用360天亚组关联较弱。
- SLAMF3/LY9区域rs4656934 G等位基因与SSRI持续使用几率降低相关。
核心结论
- 表型因素与持续抗抑郁药使用及治疗复杂度相关,多基因评分主要与治疗复杂度相关。
主要发现
- 高治疗复杂度与44项自报表型中的37项显著相关,包括吸烟率更高、复发性MDD、自杀意念、慢性疼痛及昼夜节律和非典型抑郁亚型。
- 高治疗复杂度与MDD多基因评分(β=0.04,95%CI 0.03-0.06,P=1.2×10-8)、ADHD多基因评分(β=0.03,95%CI 0.02-0.05,P=2.1×10-5)、双相障碍多基因评分(β=0.03,95%CI 0.01-0.04,P=1.2×10-4)及神经质多基因评分(β=0.02,95%CI 0.01-0.04,P=1.3×10-3)相关。
- 5453人(61%)符合独占性持续使用360天亚组标准,各亚组表型特征不同,包括与体重指数、自杀意念及共病状况的关联。
- 全基因组关联分析发现新位点,包括免疫相关基因SLAMF3/LY9,其单核苷酸变异rs4656934与SSRI持续使用几率降低相关(G等位基因;OR=0.81,95%CI 0.75-0.87,P=3.5×10-8)。
关键数值与推荐
- 持续使用360天定义为4.5年内单一抗抑郁药累计使用≥360天。
- 治疗复杂度以4.5年内处方中不同抗抑郁药类别数量评估。
临床怎么用
- 临床可关注吸烟、复发、自杀意念、慢性疼痛及非典型抑郁等表型以识别治疗复杂度高的MDD患者。
- 多基因评分目前对持续使用亚组的区分有限,尚不能用于个体化用药选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressant treatment remains a trial-and-error process: one-third of people with major depressive disorder (MDD) report inefficacy of first-line medications. Predictors of prescription patterns are needed to improve prescribing precision. OBJECTIVE: To investigate phenotypic and genetic heterogeneity of MDD subgroups defined by antidepressant prescription patterns. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of Australian Genetics of Depression Study (2017-2018) adult participants (aged ≥18 years) with lifetime MDD who filled 1 or more prescriptions of the 10 most commonly used antidepressants across 4.5 years (2013-2017). Data were analyzed from August 2024 to October 2025. EXPOSURES: Treatment complexity was assessed as number of different antidepressant classes in prescriptions filled in 4.5 years. Sustained-use 360 groups were defined as 360 or more cumulative days (in 4.5 years) of a single antidepressant. Participants with genome-wide genotypes were contrasted across mutually exclusive sustained-use 360 groups. MAIN OUTCOMES AND MEASURES: Associations of 44 self-reported phenotypes and polygenic scores (PGSs) for 15 traits with sustained-use 360 subgroups. Genome-wide association studies (GWASs) were conducted for selective serotonin reuptake inhibitor (SSRI) or SSRI/serotonin-norepinephrine reuptake inhibitor sustained use contrasted to other participants. RESULTS: Of 12 074 participants (9041 [75%] female with a mean [SD] age of 41.8 [14.6] years; 3022 [25%] male with a mean [SD] age of 47.7 [14.6] years) with 1 or more prescriptions and lifetime MDD, 8898 had genotyping data. High treatment complexity was significantly associated with 37 of 44 self-reported phenotypes (eg, higher rates of smoking, recurrent MDD, suicidal ideation, chronic pain, and circadian and atypical depression subtypes) and higher PGSs for psychiatric traits (MDD PGS: β, 0.04; 95% CI, 0.03-0.06; P = 1.2 × 10-8; ADHD PGS: β, 0.03; 95% CI, 0.02-0.05; P = 2.1 × 10-5 ; bipolar disorder PGS: β, 0.03; 95% CI, 0.01-0.04. P = 1.2 × 10-4 ; neuroticism PGS: β, 0.02; 95% CI, 0.01-0.04; P = 1.3 × 10-3). A total of 5453 (61%) met criteria for an exclusive antidepressant sustained-use 360 group. These groups had distinct phenotypic profiles, including associations with body mass index, suicidal ideation, and co-occurring conditions. GWASs identified novel loci, including an immune-related gene SLAMF3/LY9, for which single-nucleotide variant rs4656934 was associated with reduced odds of sustained SSRI use (G allele; odds ratio, 0.81; 95% CI, 0.75-0.87; P = 3.5 × 10-8). CONCLUSIONS AND RELEVANCE: This study found that phenotypic factors were associated with sustained antidepressant use and treatment complexity. PGSs for traits studied were associated with treatment complexity but showed little association with sustained-use 360 groups. These findings support further research to guide treatment selection and to identify patients at risk of difficult-to-treat depression, informing precision psychiatry and early intervention in MDD.
引用
- Walker A, Mitchell BL, Lin T, et al. Genetic and Phenotypic Associations With Sustained Antidepressant Use in Major Depressive Disorder. JAMA Psychiatry. 2026. PMID: 41604195. doi:10.1001/jamapsychiatry.2025.4372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。